Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal
RSS SUMMARY · AGGREGATED FROM TWSJ
Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.
Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.
Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.
Continue Reading
The full story continues on The Wall Street Journal.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
TWSJ
World News
Congo’s Ebola Outbreak Reaches Territory Held by Islamic State
TWSJ·1h ago·3 min read
World News
The Venezuelan Left That Fought U.S. Influence Is Now at War With Itself
TWSJ·1h ago·3 min read
Business
U.S. Crude Oil Stockpiles Post Sixth Straight Weekly Drop
TWSJ·1h ago·3 min read
Sports
James Dolan Feuded With the Whole Basketball World. Now He’s On Top of It.
TWSJ·45m ago·3 min read
Related
On this beat
Tech
Samsung rolls out 2026 Odyssey gaming monitors, including 5K and 6K models — 27 to 32 inches with up to 330 Hz refresh rate
TH·1h ago·3 min read
Tech
Samsung shows first HBM5 mockup with Heat Path Block cooling — thermal race with SK hynix shaping up
TH·59m ago·3 min read
Tech
Corsair launches lightweight budget-friendly HS35 v3 gaming headsets — wired version weighs a cool 230 grams
TH·1h ago·3 min read
Tech
PlayStation is getting back to what it’s good at
THE VERGE·1h ago·3 min read